LadRx Corp
LADX evidence brief
What we can confirm
- BioSniper Score:
- 0.4 / 10
- Market Cap:
- $50K
- Cash Runway:
- 1.1 mo
What it means
What to watch
Prepared research question
What matters most for LADX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LADX
LadRx Corp is a biopharmaceutical R&D company focused on oncology, developing novel anti-cancer drug candidates that use linker technologies to target chemotherapeutic drugs to solid tumors and reduce off-target toxicities.
Key risk: Cash runway and liquidity
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2025.
LadRx Corp is a biopharmaceutical R&D company focused on oncology, developing novel anti-cancer drug candidates that use linker technologies to target chemotherapeutic drugs to solid tumors and reduce off-target toxicities.
- LadRx is a biopharmaceutical research and development company specializing in oncology, with a focus on novel anti-cancer drug candidates that employ linker technologies to enhance tumor accumulation and reduce off-target toxicities [sec_mda · as of 2024-11-14].
- The company's discovery laboratory in Freiburg, Germany, synthesized and tested over 75 rationally designed drug conjugates in 2017, leading to two distinct classes of compounds and four lead candidates (LADR-7 through LADR-10) [sec_mda · as of 2024-11-14].
- As of 2025-03-31, LadRx reported cash & equivalents of $0.2M, net income of -$0.7M, and shareholders' equity of -$2.1M [sec].
- Research and development activities have been curtailed as the company seeks additional financing [sec_mda · as of 2023-05-15].
What works
- LadRx has a pipeline of four lead candidates (LADR-7 through LADR-10) selected from over 75 rationally designed drug conjugates, based on in vitro and animal preclinical studies [sec_mda · as of 2024-11-14].
- The company's novel linker technology aims to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor, potentially reducing off-target toxicities [sec_mda · as of 2024-11-14].
What to weigh
- LadRx has a very limited cash position of $0.2M as of 2025-03-31 and negative shareholders' equity of -$2.1M, indicating significant financial distress [sec].
- Research and development activities have been curtailed as the company seeks additional financing, suggesting a lack of near-term operational momentum [sec_mda · as of 2023-05-15].
- The company has no approved products or disclosed clinical trial data for its lead candidates, and its focus remains on early-stage preclinical development [sec_mda · as of 2024-11-14].
From the filings
Quoted directly from source documents.
LadRx is an oncology-focused biopharmaceutical R&D company.
“LadRx Corporation is a biopharmaceutical research and development company specializing in oncology.”
SEC MD&A · March 27, 2024
The company's lead candidates were selected from over 75 drug conjugates.
“During 2017, LadRx's discovery laboratory in Freiburg, Germany, synthesized and tested over 75 rationally designed drug conjugates with highly potent anti-cancer payloads, culminating in the creation of two distinct classes of compounds. Four lead candidates (LADR-7 through LADR-10) were selected based on in vitro and animal studies”
SEC MD&A · November 14, 2024
R&D activities have been curtailed due to financing needs.
“the Company's research and development activities have been curtailed as they seek additional financing.”
SEC MD&A · May 15, 2023
Risks & what to watch (3)›
Key risks
- Cash runway and liquidity — Cash & equivalents of only $0.2M as of 2025-03-31, with negative shareholders' equity, raising substantial doubt about ability to continue operations [sec].
- R&D curtailment
- No approved products or clinical data
What to watch
- Ability to secure additional financing to continue operations and resume R&D activities [sec_mda · as of 2023-05-15].
- Any preclinical or clinical updates on lead candidates LADR-7 through LADR-10 [sec_mda · as of 2024-11-14].
- Changes in cash position and shareholders' equity in future SEC filings [sec].
Sources: SEC filings · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run LadRx Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LadRx Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
1.1 months
OCF -$553K · Net income -$719K
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Short Interest
as of May 21, 2026- % of float
- 0.8%
- Days to cover
- 1.0
- Shares short
- 2,517
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LADX short interestGovernance
Frequently asked questions
What is the AI investment thesis for LadRx Corp?
LadRx Corp is a biopharmaceutical R&D company focused on oncology, developing novel anti-cancer drug candidates that use linker technologies to target chemotherapeutic drugs to solid tumors and reduce off-target toxicities.
Who is the CEO of LadRx Corp?
Stephen Snowdy is the chief executive officer of LadRx Corp (LADX).
Where is LadRx Corp headquartered?
LadRx Corp (LADX) is headquartered in Los Angeles, CA, United States.
What therapeutic areas does LadRx Corp focus on?
LadRx Corp develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.